Howse Williams (“HW”), a leading Hong Kong independent law firm, on 15 December 2025, advised the overall coordinators and placing agents, CITIC Securities and ABCI, as the Hong Kong legal counsel, on the HK$300 million placing of new H shares of PegBio Co., Ltd. (stock code: 2565).

PegBio is a biotechnology company focused on the in-house discovery and development of innovative therapies, primarily peptide and small molecule drugs, for chronic diseases with a particular emphasis on metabolic disorders.

The HW team was led by corporate partner, Brian Ho. The team had lead responsibility for legal documentation and general transaction management.

About Us

Howse Williams is a leading, full service, Hong Kong law firm. We combine the in-depth experience of our lawyers with a forward thinking approach.

Our key practice areas are corporate/commercial and corporate finance; commercial and maritime dispute resolution; clinical negligence and healthcare; insurance, personal injury and professional indemnity insurance; employment; family and matrimonial; trusts and wealth preservation; wills, probate and estate administration; property and building management; banking; fraud; distressed debt; investment funds; technology, media and telecommunications; virtual assets; financial services/corporate regulatory and compliance.

As an independent law firm, we are able to minimise legal and commercial conflicts of interest and act for clients in every industry sector. The partners have spent the majority of their careers in Hong Kong and have a detailed understanding of international business and business in Asia.

Disclaimer: The information contained in this article is intended to be a general guide only and is not intended to provide legal advice. Please contact [email protected] if you have any questions about the article.